Table 1. Predicted key allo-residues that were mutated in cancers.
| Protein | Gene | Predicted key allo-residues | Mutation* | Cancer type† |
|---|---|---|---|---|
| AR1 | AR | D732 | D732N | SKCM |
| AR2 | AR | M832 | M832I | SKCM |
| PTP-1B | PTPN1 | M282 | M282T | COAD |
| CDK2 | CDK2 | P155 | P155H | UCEC |
| CK2alpha | CSNK2A1 | F54; A110 | F54C; A110T | UCEC; UCEC, GBM |
| MAPK14 | MAPK14 | P191; E192 | P191S; P191H; E192Q | SKCM; KIRC; BLCA |
| MAPK8 | MAPK8 | E195; M200 | E195K; M200I | UCEC; SKCM |
| CYP3A4 | CYP3A4 | F219 | F219L | UCEC |
*
Mutation: confirmed disease mutations among the predicted key allo-residues.
†
Cancer type: COAD: colon adenocarcinoma; SKCM: skin cutaneous melanoma; UCEC: uterine corpus endometrial carcinoma; GBM: glioblastoma multiforme; KIRC: kidney renal clear cell carcinoma; BLCA: bladder urothelial carcinoma.